Chloe BELLOCQ

En résumé

Entreprises

• In-Cell-Art - Président et Directeur Développement de produits

  2007 - maintenant Chief Executive Officer
  Administrative and financial management of a biotechnology start-up employing 7 persons
  *Strong practice in technology transfer from academic to private field. Negotiation of 3 license agreements with INSERM/CNRS/universities.
  *Structuration, from academic research works, of a profitable service activity (CRO)
  *Business development, conclusion of partnering deals with large Pharma (Sanofi-Pasteur, Sanofi-Aventis, Merck, Merial, and other biotech companies (Innate Pharma, Geneuro, Cellectis)
  *Distribution agreements negotiation and signature for the commercialization of In-Cell-Art products in Europe (Eurogentec), Japan (Wako, Cosmo Bio), Israel (TAL RON)
  *Negotiation of option and license agreements with Sanofi Pasteur including up-front payments, clinical stage milestone payments and royalty payment
  
  R&D projects management
  *HEPAVAC project : Coordinator of a collaborative R&D project funded by the Fond Unique Interministériel (FUI 11thAAP) aiming to achieve the preclinical development of a DNA vaccine candidate for the treatment of hepatocellular carcinoma
  *RN-ARMORVAX project : Four-year R&D project involving In-Cell-Art, Sanofi Pasteur and Curevac co-funded by the Defense Advanced Research Projects Agency (DARPA), an agency of the United States Department of Defense.
  *ISI (Innovation Stratégique Industrielle) project submitted to OSEO in partnership with another biotechnology company and 2 academic laboratories –
  *Consortium member of a collaborative R&D project funded by European Commission (FP6- Health-Synthegenedelivery)

Formations

Pas de formation renseignée

Réseau

• Claire NEUVILLE

• Gaelle COUDRAY

• Guillaume CARPENTIER

• Herve PERRUCHAS

• Ludovic LANOË

• Marine HERBERT

• Muriel DARNICHE

• Olivier BIGNOLAIS

• Stéphane COLINET

• Virginie LEBREC